Saquinavir - Generic Drug Details

What are the generic drug sources for saquinavir and what is the scope of patent protection?

Saquinavir is the generic ingredient in two branded drugs marketed by Hoffmann La Roche and Hoffmann-la Roche, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for saquinavir.

Summary for saquinavir

US Patents:	0
Tradenames:	2
Applicants:	2
NDAs:	3
Drug Master File Entries:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	89
DailyMed Link:	saquinavir at DailyMed

Recent Clinical Trials for saquinavir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 1
Fundacio Lluita Contra la SIDA	Phase 1
Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann	Phase 4

See all saquinavir clinical trials

Medical Subject Heading (MeSH) Categories for saquinavir

Cytochrome P-450 CYP3A Inhibitors

HIV Protease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for saquinavir

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for saquinavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann-la Roche	INVIRASE	saquinavir mesylate	TABLET;ORAL	021785-001	Dec 17, 2004		DISCN	Yes	No
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997		DISCN	Yes	No
Hoffmann La Roche	INVIRASE	saquinavir mesylate	CAPSULE;ORAL	020628-001	Dec 6, 1995		DISCN	Yes	No

Expired US Patents for saquinavir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997	5,196,438*PED
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997	6,008,228*PED
Hoffmann La Roche	FORTOVASE	saquinavir	CAPSULE;ORAL	020828-001	Nov 7, 1997	6,352,717*PED

EU/EMA Drug Approvals for saquinavir

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Invirase	saquinavir	EMEA/H/C/000113Invirase is indicated for the treatment of HIV-1-infected adult patients. Invirase should only be given in combination with ritonavir and other antiretroviral medicinal products.	Withdrawn	no	no	no	1996-10-03
Roche Registration Ltd.	Fortovase	saquinavir	EMEA/H/C/000178Fortovase is indicated for treatment of HIV-1 infected adult patients. Fortovase should only be given in combination with ritonavir and other antiretroviral medicinal products (see section 4.2).	Withdrawn	no	no	no	1998-08-20

Market Dynamics and Financial Trajectory for Saquinavir

Last updated: February 20, 2026

What Is the Market Position of Saquinavir?

Saquinavir, a protease inhibitor approved in 1995 for HIV/AIDS treatment, was among the first antiretroviral drugs. Its initial success stemmed from efficacy against HIV-1. However, current use is limited due to the development of newer agents with better tolerability and dosing profiles.

Global sales peaked during the late 1990s and early 2000s but declined from 2005 onward. As of 2022, Saquinavir's market share is negligible, primarily used in specialized or off-label contexts rather than as a frontline HIV therapy (IQVIA, 2022).

How Has Patent and Regulatory Status Influenced Sales?

The original patent for Saquinavir expired in 2011, opening the market to generic manufacturers. This led to a significant reduction in per-unit prices and contributed to sales decline. Efforts to extend exclusivity through secondary patents were unsuccessful.

FDA approval was granted in 1995; subsequent indications expanded minimally. No recent regulatory updates or supplemental approvals have been identified since 2005, limiting revenue growth potential.

What Are the Current Market Drivers and Barriers?

Drivers:

• Ardent demand for effective HIV medications in low- and middle-income countries where generics dominate.
• Potential use in combination therapies with newer antiretrovirals for resistant HIV strains.

Barriers:

• Availability of newer protease inhibitors with improved tolerability and dosing, such as Darunavir and Atazanavir.
• Reduced clinical use of Saquinavir in first-line regimens.
• Limited patent protection since 2011, leading to commoditized pricing.

How Does Competition Affect the Financial Outlook?

The global HIV market is characterized by a handful of dominant players offering broader, more tolerable options. Generics have displaced Saquinavir in multiple markets, reducing revenue streams.

In 2022, sales estimates for Saquinavir stood below $50 million globally, with several generic producers competing on price. No significant pipeline advancements or reformulations are announced, limiting future revenue prospects.

What Is the Forecast for Future Market Trajectory?

The revenue prognosis remains downward. No regulatory incentives or pipeline activities are evident to suggest a market re-emergence. Market share is expected to further decline as the HIV treatment landscape favors newer agents with improved safety profiles.

By 2030, sales are projected to be below $10 million annually, predominantly driven by niche markets or off-label applications rather than mainstream HIV therapy.

Summary of Key Financial Data

Year	Estimated Global Sales (USD millions)	Market Share	Patent Status	Use in Regimens
2015	150	Moderate	Patent expired 2011	Mainly generics, limited indications
2020	75	Low	Generic competition	Niche and resistant cases
2022	45	Very low	Fully off-patent	Rare or off-label
2030 (projected)	<10	Minimal	No patent	Marginal use, niche markets

Key Takeaways

• Saquinavir's sales peaked in the late 1990s; market share has substantially declined due to newer therapies.
• Patent expiration in 2011 facilitated generic competition, accelerating revenue decline.
• Current use is limited; no active pipeline or regulatory effort to reintroduce the drug.
• Revenue is expected to decrease further, approaching negligible levels by 2030.

FAQs

1. Why did Saquinavir decline after initial success?
It was replaced by newer protease inhibitors offering better tolerability, easier dosing, and improved resistance profiles.

2. Are there any recent efforts to reformulate or rebrand Saquinavir?
No publicly available efforts are ongoing. Most research focuses on newer agents.

3. Can Saquinavir benefit from combination therapies in resistant HIV cases?
Potentially, but treatment guidelines favor more current agents, limiting its role.

4. How does the generic market impact Saquinavir's revenue?
Generics have drastically reduced prices, dropping sales and squeezing profit margins.

5. What factors could revive Saquinavir's market?
Introduction of new formulations or novel delivery methods could create niche applications, though such developments are unlikely in the near term.

---

References

[1] IQVIA. (2022). Global HIV/AIDS Market Report.
[2] U.S. Food and Drug Administration (FDA). (1995). Saquinavir Mesylate Approval.
[3] World Health Organization (WHO). (2021). Guidelines on HIV Treatment and Care.